On Tuesday, Biotech company Bluebird suspended its trials of gene therapy as a treatment for blood-related disorders over concerns of a possible increased risk of cancer. The company cited the recent discovery of two patients given the experimental treatment who developed a form of blood cancer, along with a similar…
